Clinical Trial Update: Phase I Study of Safety and Immunogenicity of AMA1-C1Alhydrogel + CPG 7909 Vaccine for Malaria [Phase 1]

View source ↗

Summary

A Phase I trial evaluating the safety and immunogenicity of the AMA1-C1 malaria vaccine formulated with Alhydrogel and CpG 7909; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malaria

Drugs mentioned

• AMA1-C1 malaria vaccine with Alhydrogel and CpG 7909 (AMA1-C1 malaria vaccine adjuvanted with aluminum hydroxide (Alhydrogel) and CpG 7909)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Malaria | Phase 1 | Status: COMPLETED